Scholars@Duke

• Background
• 

  Education, Training, and Certifications

  • M.D., University of North Carolina at Chapel Hill 2004
• Research
• 

  Selected Grants

  • DV3-MEL-01  awarded by Dynavax Technologies Corporation 2017 - 2022
  • IMCgp100-201  awarded by Immunocore Limited 2016 - 2021
  • Optimize BMS CA209-357  awarded by Bristol-Myers Squibb Company 2016 - 2021
  • Celldex CDX011-05  awarded by Celldex Therapeutics, Inc. 2015 - 2020
  • BMS CA209-238-0025  awarded by The Bristol-Myers/Sanofi Pharmaceuticals, Inc. Partnership 2015 - 2020
  • CA209204 A Multi-Center Phase 2 Open-Label Study to Evaluate Safety and Efficacy in Subjects with Melanoma Metastatic to the Brain treated with Nivolumab in Combination with Ipilimumab followed by  awarded by Bristol-Myers Squibb Company 2015 - 2020
  • An open label, multicenter, dose-escalation, phase 1B/2 study of the safety, efficacy, pharmacodynamics, and pharmacokin  awarded by Reata Pharmaceuticals, Inc. 2014 - 2019
  • A phase Ii trial of Neoadjuvant Ipilimumab follwed by Melphalan (L-PAM) via isolated Limb infusion (ILI) for patients wi  awarded by Bristol-Myers Squibb Company 2014 - 2018
  • Expanded access of MK-3475 in metastatic melanoma patients with limited to no treatment options  awarded by Merck Sharp & Dohme 2014 - 2015
• Publications and Artistic Works
• 

  Selected Publications

  • Journal Articles

    • Turner, MC, Rossfeld, K, Salama, AKS, Tyler, D, and Beasley, G. "Can binimetinib, encorafenib and masitinib be more efficacious than currently available mutation-based targeted therapies for melanoma treatment?." Expert opinion on pharmacotherapy 18, no. 5 (April 2017): 487-495.  Full Text
    • Hodi, FS, Chesney, J, Pavlick, AC, Robert, C, Grossmann, KF, McDermott, DF, Linette, GP, Meyer, N, Giguere, JK, Agarwala, SS, Shaheen, M, Ernstoff, MS, Minor, DR, Salama, AK, Taylor, MH, Ott, PA, Horak, C, Gagnier, P, Jiang, J, Wolchok, JD, and Postow, MA. "Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial." The Lancet. Oncology 17, no. 11 (November 2016): 1558-1568.  Full Text
    • Schadendorf, D, Dummer, R, Hauschild, A, Robert, C, Hamid, O, Daud, A, van den Eertwegh, A, Cranmer, L, O'Day, S, Puzanov, I, Schachter, J, Blank, C, Salama, A, Loquai, C, Mehnert, JM, Hille, D, Ebbinghaus, S, Kang, SP, Zhou, W, and Ribas, A. "Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma." European Journal of Cancer 67 (November 2016): 46-54.  Full Text
    • Shoushtari, AN, Munhoz, RR, Kuk, D, Ott, PA, Johnson, DB, Tsai, KK, Rapisuwon, S, Eroglu, Z, Sullivan, RJ, Luke, JJ, Gangadhar, TC, Salama, AKS, Clark, V, Burias, C, Puzanov, I, Atkins, MB, Algazi, AP, Ribas, A, Wolchok, JD, and Postow, MA. "The efficacy of anti-PD-1 agents in acral and mucosal melanoma." Cancer 122, no. 21 (November 2016): 3354-3362.  Full Text
    • Salama, AKS, and Moschos, SJ. "Next Steps in Immuno-Oncology: Enhancing Antitumor Effects Through Appropriate Patient Selection and Rationally Designed Combination Strategies." Annals of oncology : official journal of the European Society for Medical Oncology (October 13, 2016).
    • Choe, JH, Andonian, BJ, Kim, GJ, and Salama, AK. "Autoimmune meningoencephalitis in a melanoma patient treated with ipilimumab." Immunotherapy 8, no. 10 (October 2016): 1163-1167.  Full Text
    • Qin, R, Olson, A, Singh, B, Thomas, S, Wolf, S, Bhavsar, NA, Hanks, BA, Salama, JK, and Salama, AKS. "Safety and Efficacy of Radiation Therapy in Advanced Melanoma Patients Treated With Ipilimumab." International journal of radiation oncology, biology, physics 96, no. 1 (September 2016): 72-77.  Full Text
    • Coit, DG, Thompson, JA, Algazi, A, Andtbacka, R, Bichakjian, CK, Carson, WE, Daniels, GA, DiMaio, D, Fields, RC, Fleming, MD, Gastman, B, Gonzalez, R, Guild, V, Johnson, D, Joseph, RW, Lange, JR, Martini, MC, Materin, MA, Olszanski, AJ, Ott, P, Gupta, AP, Ross, MI, Salama, AK, Skitzki, J, Swetter, SM, Tanabe, KK, Torres-Roca, JF, Trisal, V, Urist, MM, McMillian, N, and Engh, A. "NCCN Guidelines Insights: Melanoma, Version 3.2016." Journal of the National Comprehensive Cancer Network : JNCCN 14, no. 8 (August 2016): 945-958.  Full Text
    • Farber, SH, Tsvankin, V, Narloch, JL, Kim, GJ, Salama, AKS, Vlahovic, G, Blackwell, KL, Kirkpatrick, JP, and Fecci, PE. "Embracing rejection: Immunologic trends in brain metastasis." Oncoimmunology 5, no. 7 (July 2016): e1172153-. (Review)  Full Text
    • Brys, AK, Bhatti, L, Bashir, MR, Jaffe, TA, Beasley, GM, Nath, NS, Salama, AKS, Tyler, DS, and Mosca, PJ. "Computed Tomography-Based Limb Volume Measurements for Isolated Limb Infusion in Melanoma." Annals of surgical oncology 23, no. 4 (April 2016): 1090-1095.  Full Text
    • Coit, DG, Thompson, JA, Algazi, A, Andtbacka, R, Bichakjian, CK, Carson, WE, Daniels, GA, DiMaio, D, Ernstoff, M, Fields, RC, Fleming, MD, Gonzalez, R, Guild, V, Halpern, AC, Hodi, FS, Joseph, RW, Lange, JR, Martini, MC, Materin, MA, Olszanski, AJ, Ross, MI, Salama, AK, Skitzki, J, Sosman, J, Swetter, SM, Tanabe, KK, Torres-Roca, JF, Trisal, V, Urist, MM, McMillian, N, and Engh, A. "Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology." Journal of the National Comprehensive Cancer Network : JNCCN 14, no. 4 (April 2016): 450-473.  Full Text
    • Barina, AR, Bashir, MR, Howard, BA, Hanks, BA, Salama, AK, and Jaffe, TA. "Isolated recto-sigmoid colitis: a new imaging pattern of ipilimumab-associated colitis." Abdominal radiology (New York) 41, no. 2 (February 2016): 207-214.  Full Text
    • Singh, BP, and Salama, AKS. "Updates in Therapy for Advanced Melanoma." Cancers 8, no. 1 (January 15, 2016). (Review)  Full Text
    • Amin, A, Lawson, DH, Salama, AKS, Koon, HB, Guthrie, T, Thomas, SS, O'Day, SJ, Shaheen, MF, Zhang, B, Francis, S, and Hodi, FS. "Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma." Journal for immunotherapy of cancer 4 (January 2016): 44-.  Full Text
    • Lowe, JR, Perry, DJ, Salama, AKS, Mathews, CE, Moss, LG, and Hanks, BA. "Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy." Journal for immunotherapy of cancer 4 (January 2016): 89-.  Full Text  Open Access Copy
    • Romain, PES, Salama, AKS, Lynn Ferguson, N, and Burbridge, RA. "Ipilimumab-Associated lymphocytic colitis: A case report." Translational Gastroenterology and Hepatology 5, no. 1 (January 1, 2016): 44-46.  Full Text
    • Howie, LJ, Tyler, DS, and Salama, AKS. "Neoadjuvant use of ipilimumab in locally advanced melanoma." Journal of surgical oncology 112, no. 8 (December 2015): 841-843.  Full Text
    • Ribas, A, Puzanov, I, Dummer, R, Schadendorf, D, Hamid, O, Robert, C, Hodi, FS, Schachter, J, Pavlick, AC, Lewis, KD, Cranmer, LD, Blank, CU, O'Day, SJ, Ascierto, PA, Salama, AKS, Margolin, KA, Loquai, C, Eigentler, TK, Gangadhar, TC, Carlino, MS, Agarwala, SS, Moschos, SJ, Sosman, JA, Goldinger, SM, Shapira-Frommer, R, Gonzalez, R, Kirkwood, JM, Wolchok, JD, Eggermont, A, Li, XN, Zhou, W, Zernhelt, AM, Lis, J, Ebbinghaus, S, Kang, SP, and Daud, A. "Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial." The Lancet. Oncology 16, no. 8 (August 2015): 908-918.  Full Text
    • Postow, MA, Chesney, J, Pavlick, AC, Robert, C, Grossmann, K, McDermott, D, Linette, GP, Meyer, N, Giguere, JK, Agarwala, SS, Shaheen, M, Ernstoff, MS, Minor, D, Salama, AK, Taylor, M, Ott, PA, Rollin, LM, Horak, C, Gagnier, P, Wolchok, JD, and Hodi, FS. "Nivolumab and ipilimumab versus ipilimumab in untreated melanoma." The New England journal of medicine 372, no. 21 (May 2015): 2006-2017.  Full Text
    • Bostwick, AD, Salama, AK, and Hanks, BA. "Rapid complete response of metastatic melanoma in a patient undergoing ipilimumab immunotherapy in the setting of active ulcerative colitis." Journal for immunotherapy of cancer 3 (January 2015): 19-.  Full Text  Open Access Copy
    • Dummer, R, Daud, A, Puzanov, I, Hamid, O, Schadendorf, D, Robert, C, Schachter, J, Pavlick, A, Gonzalez, R, Hodi, F, Cranmer, LD, Blank, C, O’Day, SJ, Ascierto, PA, Salama, AKS, Li, NX, Zhou, W, Lis, J, Ebbinghaus, S, Kang, PS, and Ribas, A. "A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma." Journal of Translational Medicine 13, no. Suppl 1 (2015): O5-O5.  Full Text
    • Gangadhar, TC, and Salama, AK. "Clinical applications of PD-1-based therapy: a focus on pembrolizumab (MK-3475) in the management of melanoma and other tumor types." OncoTargets and therapy 8 (January 2015): 929-937. (Review)  Full Text
    • Jiang, BS, Beasley, GM, Speicher, PJ, Mosca, PJ, Morse, MA, Hanks, B, Salama, A, and Tyler, DS. "Immunotherapy following regional chemotherapy treatment of advanced extremity melanoma." Annals of surgical oncology 21, no. 8 (August 2014): 2525-2531.  Full Text
    • Coit, DG, Thompson, JA, Andtbacka, R, Anker, CJ, Bichakjian, CK, Carson, WE, Daniels, GA, Daud, A, Dimaio, D, Fleming, MD, Gonzalez, R, Guild, V, Halpern, AC, Hodi, FS, Kelley, MC, Khushalani, NI, Kudchadkar, RR, Lange, JR, Martini, MC, Olszanski, AJ, Ross, MI, Salama, A, Swetter, SM, Tanabe, KK, Trisal, V, Urist, MM, McMillian, NR, and Ho, M. "Melanoma, version 4.2014." Journal of the National Comprehensive Cancer Network : JNCCN 12, no. 5 (May 2014): 621-629.
    • Beasley, GM, Speicher, P, Sharma, K, Seigler, H, Salama, A, Mosca, P, and Tyler, DS. "Efficacy of repeat sentinel lymph node biopsy in patients who develop recurrent melanoma." Journal of the American College of Surgeons 218, no. 4 (April 2014): 686-692.  Full Text
    • Beasley, GM, Speicher, P, Sharma, K, Seigler, H, Salama, A, Mosca, P, and Tyler, DS. "Efficacy of repeat sentinel lymph node biopsy in patients who develop recurrent melanoma." Journal of the American College of Surgeons 218, no. 4 (January 1, 2014): 686-692.  Full Text
    • Jiang, BS, Beasley, GM, Speicher, PJ, Mosca, PJ, Morse, MA, Hanks, B, Salama, A, and Tyler, DS. "Immunotherapy following regional chemotherapy treatment of advanced extremity melanoma." Annals of Surgical Oncology 21, no. 8 (January 1, 2014): 2525-2531.  Full Text
    • Salama, AKS, and Flaherty, KT. "BRAF in Melanoma: Current Strategies and Future Directions." CLINICAL CANCER RESEARCH 19, no. 16 (August 15, 2013): 4326-4334.  Full Text  Link to Item
    • Salama, AKS, and Kim, KB. "Trametinib (GSK1120212) in the treatment of melanoma." EXPERT OPINION ON PHARMACOTHERAPY 14, no. 5 (April 2013): 619-627.  Full Text  Link to Item
    • Shetty, G, Beasley, GM, Sparks, S, Barfield, M, Masoud, M, Mosca, PJ, Pruitt, SK, Salama, AKS, Chan, C, Tyler, DS, and Weinhold, KJ. "Plasma cytokine analysis in patients with advanced extremity melanoma undergoing isolated limb infusion." Ann Surg Oncol 20, no. 4 (April 2013): 1128-1135.  Full Text  Link to Item
    • Salama, AKS, and Kim, KB. "MEK Inhibition in the Treatment of Advanced Melanoma." Current Oncology Reports (2013): 1-10.  Full Text
    • Salama, AKS, and Kim, KB. "MEK inhibition in the treatment of advanced melanoma." Current Oncology Reports 15, no. 5 (2013): 473-482.  Full Text
    • Salama, AKS, de Rosa, N, Scheri, RP, Pruitt, SK, Herndon, JE, Marcello, J, Tyler, DS, and Abernethy, AP. "Hazard-rate analysis and patterns of recurrence in early stage melanoma: moving towards a rationally designed surveillance strategy." PLoS One 8, no. 3 (2013): e57665-.  Full Text  Link to Item
    • Salama, AKS. "Evolving pharmacotherapies for the treatment of metastatic melanoma." Clinical Medicine Insights: Oncology 7 (2013): 137-149.  Full Text
    • Gajewski, TF, Salama, AKS, Niedzwiecki, D, Johnson, J, Linette, G, Bucher, C, Blaskovich, MA, Sebti, SM, Haluska, F, and Canc, LGB. "Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104)." JOURNAL OF TRANSLATIONAL MEDICINE 10 (December 10, 2012).  Full Text  Link to Item
    • Salama, AKS, Rosa, ND, Scheri, RP, Herndon, JE, Tyler, DS, Marcello, J, Pruitt, SK, and Abernethy, AP. "The effect of metastatic site and decade of diagnosis on the individual burden of metastatic melanoma: contemporary estimates of average years of life lost." Cancer Invest 30, no. 9 (November 2012): 637-641.  Full Text  Link to Item
    • Beasley, GM, Parsons, C, Broadwater, G, Selim, MA, Marzban, S, Abernethy, AP, Salama, AKS, Eikman, EA, Wong, T, Zager, JS, and Tyler, DS. "A multicenter prospective evaluation of the clinical utility of F-18 FDG-PET/CT in patients with AJCC stage IIIB or IIIC extremity melanoma." Ann Surg 256, no. 2 (August 2012): 350-356.  Full Text  Link to Item
    • Surati, M, Robinson, M, Nandi, S, Faoro, L, Demchuk, C, Rolle, CE, Kanteti, R, Ferguson, BD, Hasina, R, Gangadhar, TC, Salama, AK, Arif, Q, Kirchner, C, Mendonca, E, Campbell, N, Limvorasak, S, Villaflor, V, Hensing, TA, Krausz, T, Vokes, EE, Husain, AN, Ferguson, MK, Karrison, TG, and Salgia, R. "Proteomic characterization of non-small cell lung cancer in a comprehensive translational thoracic oncology database." Journal of clinical bioinformatics 1, no. 8 (February 2011): 1-11.  Full Text
    • Mollberg, N, Surati, M, Demchuk, C, Fathi, R, Salama, AK, Husain, AN, Hensing, T, and Salgia, R. "Mind-mapping for lung cancer: Towards a personalized therapeutics approach." Advances in Therapy 28, no. 3 (2011): 173-194.  Full Text
    • Salama, AKS, and Hodi, FS. "Cytotoxic T-lymphocyte-associated antigen-4." Clinical Cancer Research 17, no. 14 (2011): 4622-4628.  Full Text
    • Salgia, R, Hensing, T, Campbell, N, Salama, AK, Maitland, M, Hoffman, P, Villaflor, V, and Vokes, EE. "Personalized treatment of lung cancer." Seminars in Oncology 38, no. 2 (2011): 274-283.  Full Text
    • Tretiakova, M, Salama, AKS, Karrison, T, Ferguson, MK, Husain, AN, Vokes, EE, and Salgia, R. "MET and phosphorylated MET as potential biomarkers in lung cancer." Journal of Environmental Pathology, Toxicology and Oncology 30, no. 4 (2011): 341-354.

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.